OARS funding Neuroscience

The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, support during the UH2 phase is for the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using human iPSC-derived cells representing sensory/pain neurons, brain regions, and other tissues involved in nociception, addiction and/or overdose, including tissue models of the blood-brain barrier (BBB). Support during the UH3 is for implementation of drug screens using the 3D tissue models developed during the UH2 phase. Please limit this field to a brief description of to page in length. Brevity is appreciated. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination The Common Funds Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data.

The Purpose of this FOA is to solicit cooperative agreement applications that propose clinical trials to establish the effectiveness of existing therapies and approaches for prevention and management of pain. The studies must address questions within the mission and research interests of participating NIH Institutes and Centers and evaluate preventive strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, diagnostic testing, behavioral change, rehabilitation strategies, complementary therapies, integrated approaches, and delivery system strategies in well controlled trials The overall goal is to inform clinicians about the effectiveness of interventions that will improve functional outcomes and reduce pain across the continuum of acute to chronic pain associated with many types of diseases or conditions or pain presenting as a disease itself. Clinical trials will be conducted within the infrastructure of the HEAL Pain Management Effectiveness Research Network.

The annual program aims to promote innovative research that directly supports the autism community by expanding the body of knowledge related to autism intervention and treatment, producing practical and objective results, and providing outcomes that enhance the quality of life for persons with autism and their families.

The purpose of this funding opportunity announcement is to support a practice-based research network in the United States to transform the development, delivery, and sustainability of evidence-based mental health practices and services. Through a research consortium embedded within large and integrated healthcare delivery systems (public and/or commercial systems) that serve representative populations, this Network would result in a continuously learning healthcare system as defined by the Institute of Medicine, to create a continuous cycle or feedback loop in which scientific evidence informs clinical practice while data gathered from clinical practice and administrative sources inform scientific investigation.

The Miami Initiative for Advancing, Mentoring and Investing in Women (M.I.A.M.I. WOMEN) awarded nearly $104,000 in Giving Circle grants to students and faculty during the annual Leadership Symposium on April 12, 2018. Finalists pitched their projects the previous evening at the inaugural Hawk Tank event. This grant fund is open again for the 2018-2019 cycle.

With more than fifty thousand members and certified professionals from ninety countries around the globe, the American College of Sports Medicine represents seventy occupations within the field of sports medicine. From academicians to students and from personal trainers to physicians, ACSM is dedicated to helping people worldwide live longer, healthier lives. To advance this mission, the association established the Research Grant Program through the ACSM Foundation, its charitable arm, in 1989. Through the program, grants of up to $10,000 will be awarded to support basic and applied research in exercise science. Funding is primarily targeted to new or junior investigators within seven years of attaining a terminal degree (e.g., PhD, EdD) and is expected to provide seed money support after which further funding would be sought from other sources. Grants are open to all ACSM members in good standing. See the American College of Sports Medicine website for complete program guidelines and application instructions.

This FOA invites Research and Development Center (P30) grant applications in the areas of demography and economics of aging, including relevant interdisciplinary areas rooted in population-based social science research. Areas of focus that are especially encouraged are: a) socioeconomic status (SES) disparities at older ages, including geographic disparities; b) the reasons for poor U.S. performance in health and mortality in international comparisons; c) trends and dynamics in old-age disability; d) cohort trends in obesity and its sequelae; e) family demography including the demography of care and caregiving for chronic disease, disability and Alzheimer's Disease and Alzheimer's-Related Dementias (AD/ADRD); and f) long-term supports and services for the disabled elderly population. Applications that wish to focus exclusively on AD/ADRD should submit to RFA-AG-20-002. Center grant applications must include two mandatory Cores and may choose among three optional Cores. Centers are required to work collaboratively with the Coordinating Center to be funded via RFA-AG-20-003.  

This FOA invites Research and Development Center (P30) grant applications in demography, economics and health services research relevant to Alzheimer's Disease and Alzheimer's Related Dementias (AD/ADRD). Areas of focus that are especially encouraged are: a) national and international population trends in cognitive aging and AD/ADRD; b) demography of dementia care and caregiving; c) economic burden of AD/ADRD; d) impact of health care systems and long-term supports and services on outcomes for persons with dementia and their care providers; e) impact of health care financing policies on outcomes for persons with dementia and their care providers; f) how regulatory and economic incentives affect access, quality and health outcomes in health and long-term care systems for persons with dementia; g) disparities in quality and access to dementia care; h) effects of population-level health delivery and care interventions on outcomes of persons with dementia; and i) national and international projections of dementia caseload, incidence and prevalence. Center grant applications must include two mandatory Cores and may choose among three optional Cores. Centers are required to work collaboratively with the Coordinating Center to be funded via RFA-AG-20-003.  

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimer's disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.

This broad spectrum FOA is intended to: (1) increase our understanding of how music affects the brain, body, and behavior and (2) use that knowledge to develop evidence-based music interventions to enhance health or treat specific diseases and disorders.  Proposed R01 projects can investigate how music is processed by or modifies the brain, or how it affects specific biological functions during childhood development and learning, adulthood, and aging.  Projects can also include preliminary interventions that provide a basis for therapeutic interventions. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

This FOA is intended to encourage exploratory studies to : (1) increase our understanding of how music affects the brain, body, and behavior and (2) use that knowledge to develop evidence-based music interventions to enhance health or treat specific diseases and disorders.  Proposed R21 projects can investigate how music is processed by or modifies the brain, or how it affects specific biological functions during childhood development and learning, adulthood, and aging.  Projects can also include preliminary interventions that provide a basis for therapeutic interventions. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

This Funding Opportunity Announcement (FOA) intends to support pilot studies aimed to establish molecular, anatomical, and functional cell and circuit census data from selected brain regions of young and old C57BL/6J mice. This will complement and build on current BRAIN Initiative efforts while informing a design for a comprehensive characterization of cells and circuits in the brain across the lifespan, including the generation of a comprehensive 3D brain cell reference atlas of the aging mouse brain.

This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice.  Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.

The Esther A. & Joseph Klingenstein Fund, in partnership with the Simons Foundation, has announced the opening of its 2019 competition for research fellowships in the neurosciences. Previously known as the Klingenstein Fellowship Awards in the Neurosciences, this year's awards are the second from the joint initiative. The awards are presented to highly promising early-career scientists at a point in their careers when funding can be a challenge and are designed to promote higher-risk, and potentially higher-reward, projects.

This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To this end, the McKnight Endowment Fund for Neuroscience is inviting Letters of Intent for the 2018 McKnight Technological Innovations in Neuroscience awards.